View

The Study

Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C

In simple terms

This study is like testing a new key in a lock inside a lab—it shows the key fits and turns the lock in a test model, but we don’t know if it works in real doors yet. We can’t say it will fix the problem in people.

0%

Analysis score

0/ 0

Maximum 0 for a computational/algorithm study.

Where the score came from

Reporting0
Methodology19
Publication100
Statistical77
Study type (basis of the score)
Computational/Algorithm Study
Level 5 - Expert opinion
What’s the bottom line?

Scientists made a new drug that sticks to a broken cancer protein (KRAS G12C) whether it's 'off' or 'on'. They thought this would stop cancer faster and better than old drugs that only stick when it's 'off'.

Where does this study sit?

Reviews of RCTs (Meta-analyses)

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Expert Opinion
Level 5
0

0 / 100

Quality score

Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.

Cannot establish causation

Save studies & get personalized insights

Create a free account to save this study, track new evidence as it comes in, and get breakdowns of studies in the topics you care about.

Key takeaways

Summary

Based on the study abstract and findings.

  1. 1Even though the new drug worked faster, it didn’t lead to better cancer control—meaning speed alone isn’t enough to beat the disease in these models.
  2. 2The new drug stuck to the protein 10x faster than old drugs and blocked cancer signals quicker.
  3. 3But after a few hours, both drugs blocked the protein just as much and stopped tumor growth equally well.

Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data

Publication

Journal

Nature Communications

Year

2026

Authors

Matthew L Condakes, Zhuo Zhang, Derek B. Danahy, Richard Moore, S. K. Lakkaraju, X. Zhuo, Yuka Amako, R. Borzilleri, S. Balachander, L. Chourb, Rita L. Civiello, Ashok Dongre, Daniel P Downes, D. Drexler, Brianne M Dudiak, Liudmila Dzhekieva, Miriam El-Samin, B. Fink, Kosea S. Frederick, Cherrie Huang, Javed A Khan, Emma Lees, Christopher G Levins, Courtney McCarthy, Gabriel A. Mintier, Kathy Mosure, Michael F. Parker, Ryan L Powles, Jie Qi, M. Ruzanov, Sanya Sharma, Steven Sheriff, A. Singh, Justin Stedman, Nicolas Szapiel, R. L. Thompson, Wayne Vaccaro, Tai Wang, Tianfu Yang, D. You, Matthew J. Meyer, J. Bronson, Michelle L Stewart

Open Access
3 citations
Analysis v5
Fit Body Science verdict — we translate health studies into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.